In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BI signs ten-target DART alliance with MacroGenics

Executive Summary

In one of two Big Pharma deals it signed on the same day, biologics developer MacroGenics Inc. has agreed to work with Boehringer Ingelheim GMBH on antibody-like molecules against up to ten combinations of targets, initially for immune disorders and potentially extending to cancer and respiratory, cardio-metabolic, and infectious diseases. The candidates will be generated by MacroGenics' Dual-Affinity Re-Targeting (DART) technology.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies